Media stories about Pulse Biosciences (NASDAQ:PLSE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulse Biosciences earned a news sentiment score of 0.06 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6650196219858 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Pulse Biosciences (NASDAQ:PLSE) opened at $24.01 on Thursday. Pulse Biosciences has a 1 year low of $5.20 and a 1 year high of $39.50.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.52) earnings per share for the quarter.

In other Pulse Biosciences news, Director Maky Zanganeh acquired 4,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was purchased at an average cost of $23.07 per share, for a total transaction of $92,280.00. Following the transaction, the director now owns 332,500 shares of the company’s stock, valued at approximately $7,670,775. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Robert W. Duggan acquired 22,901 shares of the firm’s stock in a transaction on Thursday, October 19th. The shares were acquired at an average price of $22.79 per share, with a total value of $521,913.79. Following the completion of the transaction, the insider now directly owns 5,820,513 shares in the company, valued at approximately $132,649,491.27. The disclosure for this purchase can be found here. Insiders have acquired a total of 2,466,594 shares of company stock valued at $36,938,410 over the last 90 days. Corporate insiders own 6.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at

About Pulse Biosciences

Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.

Insider Buying and Selling by Quarter for Pulse Biosciences (NASDAQ:PLSE)

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with's FREE daily email newsletter.